Intra-Cellular Therapies (NASDAQ:ITCI): Q4 GAAP EPS of -$0.74 beats by $0.06.
Revenue of $0.06M
https://seekingalpha.com/news/3547345-intra-cellular-therapies-eps-beats-0_06Monday, March 2, 2020
Albireo Pharma EPS beats by $1.02, beats on revenue
Albireo Pharma (NASDAQ:ALBO): Q4 GAAP EPS of -$0.57 beats by $1.02.
Revenue of $6.43M (+1028.1% Y/Y) beats by $4.9M.
https://seekingalpha.com/news/3547346-albireo-pharma-eps-beats-1_02-beats-on-revenueWave Life Sciences down 12% premarket on Q4 miss
Wave Life Sciences (WVE) Q4 results:
Revenues: $2.4M (-33.3%).
Net loss: ($56.8M) (-49.9%); loss/share: ($1.65) (-27.9%); Quick Assets: $147.2M (-15.8%).
32 mg data from both PRECISION-HD clinical trials are on track for H2.
Two additional CNS programs, SNP3 and C9orf72 are on track to initiate clinical development in H2.
Shares are down 12% premarket.
Previously: Wave Life Sciences EPS misses by $0.18, misses on revenue (March 2)
https://seekingalpha.com/news/3547351-wave-life-sciences-down-12-premarket-on-q4-missCoronavirus Spreads to Europe and Middle East—What That Means
Key Takeaways
We can predict with a high degree of confidence some outcomes—good and bad—that will emerge in the weeks ahead.
It is understandable that the latest outbreaks in Italy and Iran have sent ripples of concern around the world.
For now, every country needs to prepare—to be ready to respond if the coronavirus rears its head on its turf.
Now that the coronavirus has broken out of China and established a
foothold in Europe and the Middle East, many are on edge. This week, the
stock market for one jumped off a cliff—something it is wont to do when
faced with global uncertainty.While nothing about this global health emergency is certain, we can predict with a high degree of confidence some outcomes—good and bad—that will emerge in the weeks ahead.
Take the markets. Once they get jittery, they tend to stay jittery—until they don’t.
The coronavirus is sure to break out in different parts of the world in the weeks ahead. This will lead to new restrictive measures that will disrupt trade, supply chains and travel.
New rumors will fly on the internet and elsewhere. Public concern will spike alongside them. And politicians will burst forth lots of suggestions about what to do—and what not to do—because, well, they always feel they have to “do something” whenever a big problem is afoot.
What is also likely is that concerns may ebb as flu season comes to end. Respiratory diseases like the flu tend to wax and wane with the weather. This one will probably do the same.
Of course, the coronavirus will probably be back next flu season. But that’s the next round. We’ll have to see how well the world is prepared for that. Who knows? Perhaps a vaccine will have been developed by then.
It is understandable that the latest outbreaks in Italy and Iran have sent ripples of concern around the world.
In the case of Italy, we’re seeing a rapid spread of the disease close to the heart of Europe. That’s bound to create more disruptions.
Iran presents problems of another kind. Its health infrastructure is fragile and inadequate. Compounding that liability is its government. Corrupt, incompetent, and authoritarian, the Iranian regime is unlikely to deal responsibly with the outbreak.
Moreover, the virus is unlikely to respect boundaries in this region. There are already cases in Iraq, and the disease could easily spread to refugee camps in Syria and Jordan. War, privation and disease often travel together. And that’s very bad news for the Middle East.
So what’s the good-news prediction? The money lost in the stock market can be made back when the markets bounce back.
But the lives lost to the disease will never be restored.
For now, every country needs to prepare—to be ready to respond if the coronavirus rears its head on its turf. And there should be an extra sense of urgency in the Middle East.
The regime in Tehran should make its public health responsibilities job number one—not just for the sake of the Iranian people, but for the whole region. Unfortunately, putting the interests of others first is not something that Iran’s leaders have ever done before. So there is little reason to think that they will race to adopt the kind of responsible public health practices needed to corral the outbreak. Iran’s neighbors then will have to prepare for the worst.
https://www.heritage.org/public-health/commentary/coronavirus-spreads-europe-and-middle-east-what-means-global-health-crisis
Heron Therapeutics EPS misses by $0.09, beats on revenue
Heron Therapeutics (NASDAQ:HRTX): Q4 GAAP EPS of -$0.65 misses by $0.09.
Revenue of $35.1M (+21.7% Y/Y) beats by $3.29M.
https://seekingalpha.com/news/3547353-heron-therapeutics-eps-misses-0_09-beats-on-revenueKaryopharm up 45% premarket on positive selinexor data
Karyopharm Therapeutics (NASDAQ:KPTI) jumps 42% premarket on increased volume in reaction to positive results from a Phase 3 clinical trial, BOSTON, evaluating the combination of Xpovio (selinexor), Takeda’s (NYSE:TAK)
Velcade (bortezomib) and low-dose dexamethasone in multiple myeloma
patients who had received one-to-three prior lines of treatment.
The study met the primary endpoint of a
statistically significant improvement in progression-free survival (PFS)
compared to Velcade + dexamethasone (Vd). Specifically, median PFS in
the triplet arm was 13.93 months versus 9.46 months in the Vd arm
(p=0.007) with 30% less risk of disease progression (hazard ratio =
0.70).
Compete data will be submitted for presentation at future medical conferences.
https://seekingalpha.com/news/3547371-karyopharm-up-45-premarket-on-positive-selinexor-dataRhythm Pharmaceuticals EPS beats by $0.10
Rhythm Pharmaceuticals (NASDAQ:RYTM): Q4 GAAP EPS of -$0.78 beats by $0.10.
Cash, cash equivalents and short-term investments of $292.5M.
https://seekingalpha.com/news/3547375-rhythm-pharmaceuticals-eps-beats-0_10
Subscribe to:
Posts (Atom)